UGT2B17 and prostate carcinoma: Importantly, these results are consistent with findings from an independent study involving 2 large patient cohorts, the Canadian Prostate Cancer Biomarker Network biobank (n = 1,454) and the PROCURE cohort (n = 1,562), in which elevated UGT2B17 protein expression was reported to be associated with an increased risk of CRPC progression and prostate cancer–specific mortality (14).